Luminex

Luminex Corporation develops, manufactures, and sells biological testing technologies and products with applications throughout the life sciences and diagnostics industries. The Company's Multi-Analyte Profiling (xMAP) technology, an open architecture, multiplexing technology, allows simultaneous analysis of up to 500 bioassays from a small sample volume, a single drop of fluid, by reading biological tests on the surface of microscopic polystyrene beads called microspheres. xMAP technology combines this miniaturized liquid array bioassay capability with small lasers, digital signal processors, and software. The Company operates in two segments the technology and strategic partnerships (TSP) segment, and the assays and related products (ARP) segment.

Luminex (LMNX) delivered earnings and revenue surprises of -92.86% and 0.35%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Luminex (LMNX) Q4 Earnings Miss Estimates

Shares of Luminex (NASDAQ:LMNX) fell in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share fell 85.71% over the past year to $0.01, which missed the estimate of $0.13.

Recap: Luminex Q4 Earnings

AUSTIN, Texas, Feb. 8, 2021 /PRNewswire/ -- Luminex Corporation (Nasdaq: LMNX) today announced results for its fourth quarter and full-year ended December 31, 2020. All amounts in this release are in conformity with U.S. generally accepted accounting principles ("GAAP"). CURRENT FINANCIAL...

Luminex Corporation Reports Fourth Quarter and Full-Year 2020 Results

AUSTIN, Texas, Feb. 8, 2021 /PRNewswire/ -- Luminex Corporation (Nasdaq:LMNX) (the "Company") today announced that its board of directors declared a cash dividend for the first quarter of 2021 of $0.10 per share of common stock payable on April 15, 2021 to stockholders of record as of the...

Luminex Corporation Declares First Quarter Cash Dividend

AUSTIN, Texas, Jan. 13, 2021 /PRNewswire/ -- As previously announced, Luminex Corporation (Nasdaq: LMNX) will present at the 39th Annual J.P. Morgan Healthcare Conference, to be held virtually today, January 13, 2021 at 3:30 p.m. Central Time. A live webcast of the Luminex presentation...

Luminex Corporation to Present at 39th Annual J.P. Morgan Healthcare Conference

AUSTIN, Texas, Jan. 12, 2021 /PRNewswire/ -- Luminex Corporation (Nasdaq: LMNX) today announced 4th quarter 2020 revenue of approximately $111M, up approximately 23% over the 4th quarter of 2019 and full-year revenue of approximately $417M, up approximately 25% over the full year 2019....

Luminex Corporation Pre-Release of 4th Quarter 2020 Revenue

AUSTIN, Texas, Dec. 7, 2020 /PRNewswire/ -- On December 3, 2020, Luminex Corporation (Nasdaq:LMNX) (the "Company"), announced that its board of directors approved a $0.01 increase in the quarterly dividend, to $0.10 per share of common stock, payable on January 14, 2021 to stockholders of...

Luminex Corporation Declares Fourth Quarter Cash Dividend

Luminex (LMNX) reported earnings 30 days ago. What's next for the stock?

Why Is Luminex (LMNX) Down 0.8% Since Last Earnings Report?

Luminex (LMNX) witnessed total sample-to-answer molecular diagnostics revenue growth in the third quarter.

Luminex (LMNX) Declines 6.6% as Q3 Earnings Miss Estimates

Luminex Corporation's (LMNX) CEO Homi Shamir on Q3 2020 Results - Earnings Call Transcript

Luminex (LMNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Luminex (LMNX) Earnings Expected to Grow: Should You Buy?

AUSTIN, Texas, Oct. 22, 2020 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that it plans to report results for the third quarter ended September 30, 2020 on Thursday, November 5, 2020. A press release announcing the results is scheduled for release after the close of...

Luminex Corporation Third Quarter Earnings Release Scheduled for November 5, 2020

AUSTIN, Texas, Oct. 7, 2020 /PRNewswire/ -- Luminex Corporation (Nasdaq: LMNX) today announced 3rd quarter 2020 revenues of approximately $106 million, up approximately 35% over the 3rd quarter of 2019. Highlights include: Molecular Diagnostics revenue of approximately $60 million, up...

Luminex Corporation Pre-Release of 3rd Quarter 2020 Revenue

Becton, Dickinson and Co.

Fluidigm

Hologic

Eli Lilly

PerkinElmer

QuidelOrtho Corp

QIAGEN

You know what they say! To the most sensitive tests go the spoils.

The FDA Just Ranked Coronavirus Tests by Sensitivity. Here's What That Means

AUSTIN, Texas, Sept. 24, 2020 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that it has received a $5,389,813 award from the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response...

Luminex Receives BARDA Award to Support 510(k) Filing for NxTAG Respiratory Pathogen Panel That Includes SARS-CoV-2

AUSTIN, Texas, Sept. 23, 2020 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that it has received an award of $683,500 from the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response...

Luminex Receives BARDA Award to Support Enhancement of COVID-19 Multiplex Antibody Test

AUSTIN, Texas, Sept. 15, 2020 /PRNewswire/ -- On September 10, 2020, Luminex Corporation (Nasdaq:LMNX) (the "Company"), announced that its board of directors declared a cash dividend for the third quarter of 2020 of $0.09 per share of common stock payable on October 15, 2020 to.

Luminex Corporation Declares Third Quarter Cash Dividend

Luminex (LMNX) Down 34.6% Since Last Earnings Report: Can It Rebound?

Co-Diagnostics

GenMark Diagnostics

OPKO Health

Why Co-Diagnostics, GenMark, Luminex, and Opko Stocks Are Sinking Today

Luminex (LMNX) witnessed total sample-to-answer molecular diagnostics revenue growth in Q2

Luminex (LMNX) Q2 Earnings Beat Estimates, Revenues Miss

Luminex Corporation (LMNX) CEO Nachum Shamir on Q2 2020 Results- Earnings Call Transcript

Luminex (LMNX) delivered earnings and revenue surprises of 237.50% and -0.07%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Luminex (LMNX) Q2 Earnings Surpass Estimates

Luminex sees its Relative Strength Rating reach the elite 90-plus level.
The post Luminex Scores Relative Strength Rating Upgrade appeared first on Investor's Business Daily.

Luminex Scores Relative Strength Rating Upgrade

Shares of Luminex (NASDAQ:LMNX) moved higher by 6.77% in after-market trading after the company reported Q2 results.

Luminex: Q2 Earnings Insights

AUSTIN, Texas, Aug. 4, 2020 /PRNewswire/ -- Luminex Corporation (Nasdaq: LMNX) today announced the retirement of its Chairman, G.

News for Luminex Stock (LMNX)